Literature DB >> 3909736

The determination of specific IgA-antibodies to Yersinia enterocolitica and their role in enteric infections and their complications.

J H Larsen, S H Hartzen, M Parm.   

Abstract

Specific serum IgA-antibodies, mainly produced in the lymphoid tissue of the gastrointestinal tract (GALT) might exhibit some special characteristics deviating from IgM- and IgG-antibodies: they do not agglutinate nor fix complement. They cannot be determined by usual routine antibody techniques; indirect methods must be used. An antiglobulin-assay was used in an extensive investigation over a two-year period on sera from 8,445 patients to determine IgA-antibodies specific to Yersinia enterocolitica, serotype 3. Y. enterocolitica agglutinins were found in 965 patients, 508 of them with significant titres of greater than or equal to 80. 347 of the 2,111 patients with low titres (10 to 40) had a significantly elevated amount of IgA antibodies. The diagnoses of the IgA-positive patients fell into three groups: acute infections, acute reactive complicatory inflammations, mainly arthritis, chronic inflammatory connective tissue diseases. The IgA-antibody pattern was: In early samples from patients with acute enteric infections they might be the only antibodies present following, largely, during the course of the disease the agglutinating IgM and IgG antibodies, except in patients with long-lasting or chronic complications where IgA antibodies were elevated. It is concluded that determination of specific antibodies of IgA class in cases of Y. enterocolitica infections is an important diagnostic test and, moreover, of prognostic value in the evaluation of chronicity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3909736     DOI: 10.1111/j.1699-0463.1985.tb02897.x

Source DB:  PubMed          Journal:  Acta Pathol Microbiol Immunol Scand B        ISSN: 0108-0180


  9 in total

1.  Influence of antibiotics on IgA and IgG response and persistence of Yersinia enterocolitica in patients with Yersinia-associated spondylarthropathy.

Authors:  J A Hoogkamp-Korstanje; J de Koning; J Heesemann; J J Festen; P M Houtman; P L van Oyen
Journal:  Infection       Date:  1992 Mar-Apr       Impact factor: 3.553

2.  Comparison of bacteria with and without plasmid-encoded proteins as antigens for measurement of immunoglobulin M, G, and A antibodies to Yersinia enterocolitica by enzyme-linked immunosorbent assay.

Authors:  K Granfors; R Lahesmaa-Rantala; T H Ståhlberg; A Toivanen
Journal:  J Clin Microbiol       Date:  1989-03       Impact factor: 5.948

3.  Estimates of incidence and costs of intestinal infectious diseases in the United States.

Authors:  W E Garthright; D L Archer; J E Kvenberg
Journal:  Public Health Rep       Date:  1988 Mar-Apr       Impact factor: 2.792

4.  Comparison of crossed immunoelectrophoresis, enzyme-linked immunosorbent assays, and tube agglutination for serodiagnosis of Yersinia enterocolitica serotype O:3 infection.

Authors:  A Paerregaard; G H Shand; K Gaarslev; F Espersen
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

5.  Decomplementation by cobra venom factor suppresses Yersinia-induced arthritis in rats.

Authors:  K I Gaede; E Baumeister; J Heesemann
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

6.  Human coproantibody secretory immunoglobulin A response to Yersinia species.

Authors:  K M Fletcher; C M Morris; M A Noble
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

7.  Persistence of Yersinia enterocolitica in man.

Authors:  J A Hoogkamp-Korstanje; J de Koning; J Heesemann
Journal:  Infection       Date:  1988 Mar-Apr       Impact factor: 3.553

8.  Association of persisting IgA response with yersinia triggered reactive arthritis: a study on 104 patients.

Authors:  A Toivanen; R Lahesmaa-Rantala; R Vuento; K Granfors
Journal:  Ann Rheum Dis       Date:  1987-12       Impact factor: 19.103

9.  Cationic Yersinia antigen-induced chronic allergic arthritis in rats. A model for reactive arthritis in humans.

Authors:  A K Mertz; S R Batsford; E Curschellas; M J Kist; K B Gondolf
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.